Exagen to Announce Third Quarter 2024 Results on November 12, 2024
Exagen (Nasdaq: XGN), a provider of autoimmune testing, will release its third quarter 2024 financial results on November 12, 2024, before market opens. The company will host a conference call at 8:30 AM ET with President and CEO John Aballi and CFO Jeff Black. Investors can join via phone or webcast through the company's investor relations website. A replay will be available until November 26, 2024, through phone or webcast recording.
Exagen (Nasdaq: XGN), fornitore di test autoimmuni, rilascerà i suoi risultati finanziari del terzo trimestre 2024 il 12 novembre 2024, prima dell'apertura del mercato. L'azienda ospiterà una conferenza telefonica alle 8:30 AM ET con il Presidente e CEO John Aballi e il CFO Jeff Black. Gli investitori possono partecipare tramite telefono o webcasting attraverso il sito web delle relazioni con gli investitori dell'azienda. Una registrazione sarà disponibile fino al 26 novembre 2024, tramite registrazione telefonica o webcasting.
Exagen (Nasdaq: XGN), proveedor de pruebas autoinmunes, publicará sus resultados financieros del tercer trimestre de 2024 el 12 de noviembre de 2024, antes de la apertura del mercado. La compañía organizará una conferencia telefónica a las 8:30 AM ET con el Presidente y CEO John Aballi y el CFO Jeff Black. Los inversores podrán unirse por teléfono o a través de la transmisión web en el sitio web de relaciones con inversores de la compañía. Una repetición estará disponible hasta el 26 de noviembre de 2024, a través de grabaciones telefónicas o de transmisión web.
Exagen (Nasdaq: XGN), 자가면역 검사 제공 업체, 2024년 3분기 재무 결과를 2024년 11월 12일, 시장 개장 전에 발표할 예정입니다. 회사는 오전 8시 30분 ET에 사장 겸 CEO 존 아발리 및 CFO 제프 블랙과 함께 컨퍼런스 콜을 진행합니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 전화 또는 웹캐스트로 참여할 수 있습니다. 재생은 2024년 11월 26일까지 전화 또는 웹캐스트 녹화를 통해 제공됩니다.
Exagen (Nasdaq: XGN), fournisseur de tests auto-immuns, publiera ses résultats financiers du troisième trimestre 2024 le 12 novembre 2024, avant l'ouverture du marché. L'entreprise animera une conférence téléphonique à 8h30 (heure de l'Est) avec le Président et CEO John Aballi et le CFO Jeff Black. Les investisseurs peuvent se joindre par téléphone ou par webdiffusion via le site web des relations avec les investisseurs de l'entreprise. Un enregistrement sera disponible jusqu'au 26 novembre 2024, via un enregistrement téléphonique ou de webdiffusion.
Exagen (Nasdaq: XGN), Anbieter von Autoimmununtersuchungen, wird seine Finanzergebnisse für das dritte Quartal 2024 am 12. November 2024 vor Markteröffnung veröffentlichen. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz mit Präsident und CEO John Aballi sowie CFO Jeff Black veranstalten. Investoren können telefonisch oder per Webcast über die Investor-Relations-Website des Unternehmens teilnehmen. Eine Wiederholung wird bis zum 26. November 2024 über telefonische oder Webcast-Aufzeichnungen verfügbar sein.
- None.
- None.
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024, before the market opens on Tuesday, November 12, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).
Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.
A replay of the conference call will be available until Tuesday, November 26, 2024, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13749452. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow @ExagenInc on X.
Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525
FAQ
When will Exagen (XGN) release Q3 2024 earnings?
How can investors access Exagen's (XGN) Q3 2024 earnings call?
Until when will Exagen's (XGN) Q3 2024 earnings call replay be available?
